Invasive squamous cell carcinoma and sorafenib in a black patient.
Matthew R
MR
Donaldson
Cloyce L
CL
Stetson
Jennifer L
JL
Smith
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D044383:Black People; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000473:pathology; D003875:Drug Eruptions / Q000209:etiology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib